Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDeate-Prostate01: ifinatamab deruxtecan versus docetaxel in metastatic castration-resistant prostate cancer
MOH_2025-05-05_014044Phase 3Not yet recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Ifinatamab deruxtecan with Docetaxel + prednisone (2 arms). Primary endpoints: Overall survival and Radiographic progression-free survival. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
ifinatamab deruxtecandocetaxelprednisone
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2025-05-05_014044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-05-05_014044.